The Trump administration is reportedly scaling back its involvement in global HIV/AIDS prevention and treatment programs, particularly in South Africa, marking another significant shift in U.S. foreign aid policies. The decision to wind down participation in the President's Emergency Plan for AIDS Relief (PEPFAR) in South Africa has sparked controversy and raised concerns about the potential impact on public health in the region.
According to an anonymous source within the U.S. State Department, the administration's decision to reduce funding to South Africa stems from allegations that the country has failed to adequately protect its white Afrikaner population from what President Donald Trump has described, without providing evidence, as a "genocide." This claim forms the basis of a broader policy shift that includes the suspension of much of the U.S. humanitarian and development aid to South Africa earlier this year. The move was accompanied by provisions allowing white Afrikaners to seek refugee status in the United States, despite the administration's overall stance on limiting immigration and refugee admissions.
PEPFAR, launched in 2003 under former President George W. Bush, has long been regarded as one of the most effective international health initiatives supported by the United States. It has contributed to saving millions of lives worldwide, including in South Africa, where it has played a crucial role in combating the spread of HIV/AIDS. Over the years, PEPFAR has provided approximately $8 billion in assistance to South Africa, contributing roughly 17% of the nation’s annual HIV budget, which amounts to about $400 million each year.
The implications of ending PEPFAR support in South Africa could be severe given the scale of the HIV epidemic in the country. South Africa has the highest number of HIV-positive individuals globally, with an estimated 7.8 million cases, representing nearly 13% of the population. A recent study suggests that the full withdrawal of PEPFAR funding could result in between 1.1 and 2.1 million new HIV infections over the next two decades, along with the deaths of between 519,000 and 712,000 people during the same period.
South Africa has recently begun implementing a new HIV medication known as lenacapavir, which is administered via injection twice annually and offers a significant reduction in the risk of contracting the virus. However, the availability of this drug is currently constrained by its high cost—approximately $28,000 per person per year—with a more affordable generic version expected to become available next year at around $40 per person. Despite this anticipated decrease in price, the lack of sustained financial backing from PEPFAR raises concerns about the ability of South Africa to ensure widespread access to the medication.
Moreover, the Trump administration has reportedly excluded South Africa from a State Department initiative aimed at distributing up to 2 million doses of lenacapavir to several countries facing high demand for the drug. This exclusion underscores the potential limitations imposed by the current administration's policies on the availability of essential medicines in regions heavily affected by HIV/AIDS.
As South Africa continues its efforts to combat the HIV/AIDS crisis, the reduction in U.S. support poses additional challenges. Previous cuts to PEPFAR funding have already impacted community-based health services, including HIV testing and access to preventive medications. These effects are exacerbated by increased wait times and overworked healthcare personnel, making it difficult for individuals requiring medical attention to obtain timely care. With the ongoing uncertainty surrounding future funding commitments, the outlook for maintaining and expanding HIV/AIDS prevention and treatment programs in South Africa remains uncertain.
★
Keep the news honest.
ObjectiveNews is reader-funded and ad-free — we show you the bias instead of hiding it. Support independent journalism for €5/month.
Become a Supporter
